Efficacy and safety of AVIANDR in the treatment of panic disorder: results of the first stage of the multicenter, randomized, placebo-controlled study
Aviandr demonstrated statistically significant superiority over placebo, rapid onset of action, and a favorable safety profile, making it a promising treatment option for panic disorder.
Authors
- A.E. Morozov
- V.G. Zilov
- E.A. Smolyarchuk
- A.K. Vasyuta (ORCID: https://orcid.org/0000-0002-3457-5123)
- A V Ivaschenko
- A A Ivaschenko
- T.F. Bogatov (ORCID: https://orcid.org/0009-0000-1148-2787)
- K.A. Vasko
- T. A. Izyumina
- E. M. Goncharova
- V. V. Tarasov
- N. N. Ivanets
- D. S. Gorchakov
- E. N. Morozov
- O. V. Izmailova
- N.A. Penchul
- P.A. Belyaeva
- I.V. Balaban
- O.R. Moskovtseva
- D.Ch. Mavani
- B.A. Volel
- K.K. Gylypkylova
Institutions
- Sechenov University (RU)
- Lomonosov Moscow State University (RU)
- Leningrad Regional Cancer Center (RU)
- Niepubliczna Wyższa Szkoła Medyczna (PL)
- Nova Medical (United States) (US)
- Samara State Medical University (RU)
- ChemDiv (United States) (US)
- Association of Child Psychotherapists (GB)
- State Healthcare Institution "Regional Clinical Oncological Dispensary" (RU)
- Moscow State University (TJ)
- Health and Safety Executive (GB)
Publication Details
- Journal
- S S Korsakov Journal of Neurology and Psychiatry
- Published
- 2025-12-30
- DOI
- https://doi.org/10.17116/jnevro2025125121161
- Primary Topic
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Type
- article
- Field-Weighted Citation Impact
- 0.00